Ollin Biosciences has completed a $330 million Series B financing round to fund global Phase 3 trials of OLN324, a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE